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The purpose of this study was to investigate the relationships between clinical factors (including haemoglobin value,
chemotherapeutic agents, and corticosteroid use) and changing patterns of fatigue before and for the next 10 days following the
start of a new round of chemotherapy in children with cancer. A prospective longitudinal design was used to collect data from 48
paediatric oncology patients who were about to begin a new round of chemotherapy and their parents. Fatigue levels were assessed
using multidomain questionnaires with three categories of patient self-report (including ‘General Fatigue’, ‘Sleep/Rest Fatigue’, and
‘Cognitive Fatigue’) and four categories of parent proxy-report (including ‘Lack of Energy’, ‘Unable to Function’, ‘Altered Sleep’, and
‘Altered Mood’). The findings suggest that fatigue from both patient self-report and parent proxy-report changed significantly over
time. The major findings from this study are that patients have more problems with fatigue in the first few days after the start of a
cycle of chemotherapy. Corticosteroid use and haemoglobin value were associated with significant increases in fatigue that were
sustained for several days and reached the highest level of fatigue at day 5 for those receiving concurrent steroids. The association of
chemotherapeutic agents with fatigue varied between patient self-report and parent report, but the type of chemotherapeutic agents
used was not associated with most changes in fatigue.
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Fatigue is one of the most frequent and severe symptoms
experienced by paediatric oncology patients during treatment
(Hockenberry-Eaton et al, 1998; Hinds et al, 1999; Wolfe et al,
2000; Collins et al, 2002). It is also among the most distressing
symptoms reported in the terminal phase of their illness (Wolfe
et al, 2000; Jalmsell et al, 2006; Theunissen et al, 2007). However,
very few quantitative studies have reported on fatigue in paediatric
oncology patients (Varni et al, 2002; Langeveld et al, 2003).
Aggressive treatment of paediatric oncology patients is focused on
cure; therefore, side effects, such as fatigue, that result from
treatments may be ignored by clinicians (Hockenberry-Eaton and
Hinds, 2000) or considered as unavoidable symptoms that need to
be endured (Gibson et al, 2005).
The development of the proposed models for fatigue is based on
adult oncology patients (Piper, 1986; Nail and Winningham, 1993;
Wessely et al, 1998). The management of fatigue is an important
clinical issue because fatigue is recognised as having a greater
impact on patients than other mental or physical consequences of
cancer or its treatment (Stone et al, 2000; Ahlberg et al, 2005).
Fatigue is complex and is often associated with multiple
physiological and emotional sequelae. Few studies have examined
the aetiology of fatigue associated with chemotherapy treatment
(CTX). In a study that evaluated the epidemiology of cancer-
related fatigue in 419 adult cancer patients, 74% of the patients
considered fatigue as a symptom to be endured and 80% of the
oncologists believed fatigue is undertreated (Vogelzang et al,
1997). Fatigue may exist before, during, and after CTX for cancer
(Langeveld et al, 2000). Stasi et al (2003) proposed that fatigue
would be more intense in the first few days after CTX and then
would gradually abate until the next course of CTX. However, little
empirical evidence exists to support this statement.
Factors that may contribute to fatigue intensity, such as anaemia
(Wang et al, 2002) and the role of cortisol (Payne, 2004), are not
well documented. Corticosteroids are essential in the treatment of
acute lymphoblastic leukaemia, which represents the majority of
cancers diagnosed in childhood (Gaynon and Lustig, 1995).
However, the relationship between fatigue and treatment protocols
including the use of corticosteroids has not been investigated in
detail.
Identifying the specific factors associated with the fatigue that
accompanies CTX could provide important information to
clinicians and researchers. Clinicians would be able to assess and
treat these symptoms, not only making the children more
comfortable but increasing patient and parent satisfaction as well
(Braud et al, 2003). It is important for clinicians to acknowledge
the impact of fatigue and, whenever possible, provide therapeutic
interventions to decrease it. Thus, the purpose of this study was to
investigate changing patterns of fatigue by enrolling paediatric
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soncology patients just before the start of a new round of CTX and
then following them for 10 days. Factors that may contribute to
fatigue, including chemotherapeutic agents, corticosteroid use
during the study period, and haemoglobin value, were also
examined.
MATERIALS AND METHODS
A prospective longitudinal design was used to evaluate fatigue in
paediatric oncology patients who received CTX. Each subject and
their parent provided data about the child’s fatigue experiences
before CTX and each of the next 10 days.
Participants
Participants were children with cancer and their parents. Children
were eligible for this study if they were aged 7–18 years, were
diagnosed with cancer, were prescribed CTX, and were not
receiving concomitant radiation or had not undergone bone
marrow transplantation. All children were prescribed one of the
following chemotherapeutic agents: methotrexate, vincristine,
etoposide, cisplatin, cytarabine, epirubicin, or cyclophosphamide.
Data of concomitant corticosteroids used as part of the protocol
for the CTX cycle were also collected. If a patient received
corticosteroids for treatment purposes, other than a component of
their CTX protocol, they were excluded from this study.
Corticosteroids used included prednisolone, hydrocortisone, or
dexamethasone. Owing to different CTX protocols, participants
were enrolled in this study when they were about to receive a new
round of CTX and their first fatigue assessment could be made on
the day before the new round was started. Additional assessments
were made 24h after the CTX had begun (i.e., day 02) and then
daily for the next 9 days. The research team selected 11 days as the
timeframe to allow sufficient time for symptoms to change, as well
as for administration of chemotherapeutic agents and steroids. In
most CTX protocols, these agents were administered within a
week, and this allowed at least 3 days to collect data on the
resulting symptoms. Fifty-two patients were approached and two
patients declined because of parental time constraints. Two other
patients who had been on CTX for a more extended period of time
(greater than 30 months) were also excluded. In total, data were
collected from 48 patients and 48 parents. Table 1 presents the
detailed demographic and diagnostic characteristics of the
children.
Measures
The conceptual definition used in this study was defined by our
previous qualitative study of exploring the fatigue experiences
reported by Taiwanese children with cancer (Chiang et al, 2008b).
Fatigue is defined as ‘a phenomenon that includes both physical
and psychosocial sensations (e.g., tiredness, lack of energy, and
lack of motivation) as well as consequences (e.g., lying on the bed
and being unable to engage in physical activities)’ (Chiang et al,
2008b). Owing to the limited number of fatigue measurement tools
available at data collection, two existing instruments were used to
collect data for this study. The PedQL Multidimensional Fatigue
was administered to the patients and the Parent Fatigue Scale
(PFS) was used for the parents. Both were originally designed and
tested in English. For our studies, both measures were translated
from English into Chinese language. The detailed process of
translation and back translation is described in another publica-
tion (Chiang et al, 2008a).
PedsQL Multidimensional Fatigue scale
The PedsQL Multidimensional Fatigue scale (Varni et al, 2002) was
used to measure patients’ self-reported fatigue symptoms. It
consists of three subscales, including ‘General Fatigue’ (six items),
‘Sleep/Rest Fatigue’ (six items), and ‘Cognitive Fatigue’ (six items).
All items used a five-point Likert response set, ranging from
1¼‘not at all’ to 5¼‘always’. To assess the detailed pattern of
fatigue during chemotherapy for paediatric oncology patients, a
new version of the PedsQL Multidimensional Fatigue scale, one
that was intended for daily assessment of fatigue for the past 24h,
was developed and tested (Chiang et al, 2008a). The reliabilities of
the three subscales and total scale in the 24-h version ranged
between 0.83 and 0.93 (Cronbach’s a coefficient) and the validity
was also evident with high correlation with the Chinese version of
the Fatigue Scale-Children (Pearson correlation values ranged
from 0.36 to 0.56) (Chiang et al, 2008a). In the original instrument,
higher scores indicated fewer symptoms of fatigue. To compare the
fatigue change patterns for patients and parents, the PedsQL
Multidimensional Fatigue Scale used in the current study was
rescored so that higher scores indicated that patients had increased
fatigue. Cronbach’s a values for the various subscales ranged from
0.91 to 0.95 for this study.
The Parent Fatigue Scale
The PFS (Hockenberry et al, 2003) was used to measure parental
perception of their child’s fatigue over the previous 24h. The PFS
included four fatigue subscales: ‘Lack of Energy’ (six items),
‘Unable to Function’ (three items), ‘Altered Sleep’ (four items), and
‘Altered Mood’ (four items). All items used a five-point Likert
response set, ranging from 1¼‘not at all’ to 5¼‘always’. Higher
scores indicated that parents perceived that their child experienced
greater fatigue. Good reliability has been reported in previous
studies with this instrument (Cronbach’s a for the total scale was
0.88) (Hockenberry et al, 2003). Strong correlation with the child’s
self-report of fatigue, as well as convergent validity with other well-
established measures, was also reported (Hockenberry et al, 2003).
Cronbach’s a values for the subscales ranged from 0.61 to 0.87 for
this study.
Demographic information
Demographic and relevant data were collected from medical
records and included age, gender, cancer diagnosis, haemoglobin
level, body weight, and treatment information. Haemoglobin level
at the baseline assessment (i.e., from blood drawn on the day
before the first dose of that round of CTX) was available for all
patients. For some patients (n¼17), haemoglobin was assessed
Table 1 Demographic characteristics of patients
Variables n %
Age
Mean (s.d.) (range) 11.51 (2.95) (7–17)
Gender
Male 26 54
Female 22 46
Duration since initial diagnosis (months)
Mean (s.d.) (range) 4.37 (4.53) (0–21)
Type of disease
Leukaemia 25 52
Lymphoma 2 4
Solid tumour 17 36
Brain tumour 4 8
Illness stages
Newly diagnosed within 2 months 18 38
Remission on treatment 30 62
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sonly at baseline. However, the remaining patients (n¼31) had at
least one haemoglobin assessment during follow-up. Use of
chemotherapeutic agents and corticosteroids before baseline
assessment and on each day during data collection was also
recorded.
Procedures
The study began after receiving approval from the Human Subjects
Review Committee at Chang Gung Children’s Hospital in Taiwan.
The hospital’s established procedures for protecting confidentiality
were strictly followed. The patients in the study setting who were
about to receive CTX at the hospital ward and who met the
sampling criteria were approached by a trained research assistant
(RA). The parents received verbal and written explanations of the
study and procedures and were asked about their willingness to
participate in this study along with their sick child. After parental
consent and child assent were obtained, they were scheduled and
interviewed in person at the hospital wards by a trained
interviewer. Each patient and their parent were interviewed
independently by face-to-face interviews in the hospital or by
telephone if the patient was no longer hospitalised at the time of
data collection. The RA administered the questionnaire package in
person at the hospital for the baseline assessment and collected
follow-up assessment data either in person or by phone if a patient
had been discharged during the data collection period. Following
data collection, identity of patients and parents was removed and
all identifiable materials were stored in a locked office.
Data were collected at 11 time points, baseline (pre-CTX) and
daily for 10 consecutive days. The data were collected at the same
time each day (i.e., in the morning before the CTX began for that
day).
Data analysis
Descriptive statistics were calculated for the demographic char-
acteristics of the patients. It was expected that the items within
each subscale of fatigue could contribute differently to the
underlying fatigue construct. Thus, rather than simply adding
the scores for all items within a subscale, the score for each
subscale was calculated using the factor scores obtained from a
single-factor analysis. The ranges of scores for each subscale were
converted to the range of 1–5 so that the different fatigue levels
could be directly compared. A multivariate mixed-effects model
(using the MIXED Procedure in SAS) (SAS Institute Inc., 2006) was
used to capture the longitudinal outcome measures (modelling
covariance across time) as well as the high correlation between the
multidomain outcomes (modelling covariance across the multi-
variate observations, such as General, Sleep/Rest, and Cognitive
Fatigue for patient-reported data) (Galecki, 1994).
To account for the multivariate nature of the data (multiple
correlated symptoms over time), a direct-product covariance
structure (UN@AR(1)), available in PROC MIXED (SAS Institute
Inc., 2006), was used. Patient self-reported and parent proxy-
reported data were modelled separately, because the instruments
used measured slightly different concepts associated with fatigue.
The model included fixed effects for time, cumulative CTX agent
and cumulative corticosteroid use before baseline assessment and
through each study day, and current haemoglobin level. Missing
current haemoglobin values were imputed using the most recently
observed haemoglobin values for each patient (for 17 patients,
baseline haemoglobin value was used throughout). For each study
day, chemotherapeutic agent use and corticosteroid use were each
coded as 0¼‘not used’ and 1¼‘used’. Then, to examine the
cumulative relationship with fatigue factors, the cumulative use of
chemotherapeutic agents and corticosteroids before the baseline
assessment and through each day in this cycle of CTX was
calculated and used as a covariate in the model. Model effects were
tested at a significance level of 0.05. Data analyses were performed
using SAS software, version 9.1.3 (SAS Institute Inc., 2006).
RESULTS
Characteristics of participants
The patients included 26 males and 22 females. The mean age of
the patients was 11.51 years (range 7–17, s.d.¼2.95 years). Cancer
diagnoses included leukaemia (n¼25), lymphoma (n¼2), solid
tumour (n¼17), and brain tumours (n¼4). The average duration
for receiving CTX before the current cycle was 4.37 months (range
0–21.23, s.d.¼4.53 months), including eight patients who were
newly diagnosed and were receiving their first round of CTX; 10
had been treated for less than 2 months, 11 between 2 and 4
months, and 19 had been treated for more than 4 months. Twenty-
six (54%) patients received corticosteroids. The parents included
41 mothers, 6 fathers, and 1 adult family member.
Change patterns of fatigue
Figures 1 and 2 present the unadjusted means of factor scores of
fatigue for patients’ self-reports and parents’ proxy-reports,
respectively. Patterns of change in fatigue were determined across
the 11 time points. After adjusted by cumulative days of CTX,
steroids used before baseline assessment, haemoglobin value, and
cumulative chemotherapeutic agent and corticosteroid use for
each study day, time was associated with changes in the fatigue
scores (Po0.001) for patient self-reported data, which indicates
that patients in this study report statistically significant fatigue
when the subscales of fatigue were treated as a multidomain
construct. General Fatigue increased after CTX was administered
to its highest level on day 2 and then gradually decreased over
time. Sleep/Rest Fatigue levels also increased after CTX and
reached the highest level on day 3, but this change was not
significant over 11 time points (P¼0.21) after controlled by other
factors. Cognitive Fatigue did not change significantly over the
course of the study (P¼0.95), although its observed change
pattern appears similar to subscales of General Fatigue and Sleep/
Rest Fatigue.
For parents’ proxy-reported fatigue scores, all four of the
domains of fatigue changed significantly over time (Po0.001).
From Figure 2, the unadjusted fatigue mean scores of Lack of
Energy and Unable to Function increased immediately after CTX
was administered and reached the highest levels of fatigue on day 1
and then gradually decreased until day 10; however, Unable to
Function had a small peak at day 5. Altered Mood reached its
highest intensity level on day 5 and then decreased thereafter.
Altered Sleep showed a small fluctuation until day 5, but generally
decreased until day 10.
Factors associated with the patterns of change in fatigue
For patients’ self-reported fatigue scores, the cumulative use of
corticosteroids before baseline assessment and during study day,
chemo drugs before baseline assessment, and haemoglobin were
significantly associated with increased fatigue for all three
subscales (i.e., General Fatigue, Sleep/Rest Fatigue, and Cognitive
Fatigue). Chemotherapeutic drug administration during the study
days was not associated with fatigue change.
Figure 3 compares the unadjusted mean scores of fatigue change
patterns for patient self-reported data over time for those patients
who ever received corticosteroids and those who did not
(descriptive data for fatigue factor scores are not presented here
but are available on request). Among those patients who did not
receive corticosteroids, the General Fatigue, Sleep/Rest Fatigue,
and Cognitive Fatigue scales decreased fairly consistently.
However, for those patients who were given at least 1 day of
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scorticosteroids during this period, all three scales increased from
baseline to day 3 or 4. Day 4 or 5 had the maximum differences on
the Sleep/Rest Fatigue scale. After controlling for haemoglobin and
cumulative use of CTX agents, the means of all three scales were
significantly higher for those using corticosteroids consecutively
than for those who did not.
For parent proxy-reported data, higher levels of Lack of Energy,
Altered Sleep, and Altered Mood were significantly associated with
increasing cumulative corticosteroid use and a decrease in
haemoglobin value (Po0.001). Figure 4 shows that the unadjusted
fatigue mean scores of corticosteroids appear to increase all
fatigue scores in the beginning, even though the increase is
very slow, besides Unable to Function, which had a sudden jump at
day 1, but decreased later, and had another jump at Day 5. In
addition, before Day 2, patients who did not use corticosteroids
had a higher fatigue score in Unable to Function than those
without corticosteroid use. Generally speaking, all of the
unadjusted fatigue mean scores reached their highest average
value on day 4 or 5 for patients who received corticosteroids. After
controlling for haemoglobin and cumulative use of CTX agents and
corticosteroids, the mean of the Lack of Energy, Altered Sleep, and
Altered Mood scores was significantly higher for those patients
who used corticosteroids than for those who did not; although
nonsignificant, a consistent pattern was observed for the Unable to
Function scale as well.
DISCUSSION
This prospective longitudinal study is the first to document clinical
factors associated with patterns of change in fatigue during a
round of CTX, experienced by children with cancer in Taiwan. The
major findings from this study are that patients have more
problems with fatigue in the first few days after the start of a cycle
of CTX. The administration of corticosteroids and haemoglobin
value are associated with significant increases in fatigue that are
sustained for several days and reach the highest level of fatigue at
Day 5 for those using steroids consecutively. Of note, parent
proxy-report data and patient self-report data indicated different
factors associated with changes in fatigue. We preface the detailed
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Figure 2 Unadjusted factor mean scores of fatigue change patterns over time reported by parents.
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Figure 1 Unadjusted factor mean scores of fatigue change patterns over time reported by children.
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sdiscussion of our results by listing several limitations that should
be considered. First, although all children suffered from cancer
and all had been receiving CTX for less than 22 months, several
different CTX protocols were being used to treat the children in
this study. Additionally, there were several different cancer
diagnoses among the children studied. As an example, children
with brain tumours may have had more pre-existing issues with
fatigue than some of the other children. Lastly, all children had
haemoglobin levels drawn on day 1, before starting their round of
CTX; however, 35% of the children did not have subsequent
haemoglobin levels drawn during the next 10 days of data
collection. Another limitation of this study that may affect its
interpretation is that the assessment of fatigue by patient self-
report and that by parent proxy-report are similar but showed
slight variation. Thus, it is not possible to directly examine the
validity of proxy-reported fatigue for patient self-reported and
parent proxy-reported data. The reason for choosing these two
versions is the limited established validity of the instruments in the
Taiwanese population. Several authors agree that fatigue is a
subjective construct (Hinds et al, 1999; National Comprehensive
Cancer Network, 2006; Ream et al, 2006) and that it should be
assessed directly by the patients self-report. However, the fact that
children who are ill are providing these data and their cognitive
and linguistic levels vary makes using only patient self-reported
data less reliable (Chang and Yeh, 2005). Furthermore, brief
questionnaires are needed to minimise the burden to young
subjects. For example, in a study comparing quality of life
measured using both child self-report and parent proxy-report
(Chang and Yeh, 2005), it was determined that children younger
than 12 years of age provided different perspectives of subjective
domains of quality of life from parental report. In addition, when
parents assess patient’s fatigue, parents’ own fatigue may influence
their judgment of patient’s fatigue.
The widely recognised definition of fatigue in paediatric
oncology patients is ‘profound sense of being physically tired, or
having difficulty with body movement such as using their arms
and legs, or opening their eyes’ for children (Hockenberry et al,
2003, p 320) and ‘a changing state of exhaustion that could include
physical, mental and emotional tiredness’ for adolescents
(Hockenberry et al, 2003, p 320). The behaviours of fatigue are
observable by parents and clinicians. Thus, the assessment of
fatigue for paediatric oncology patients needs to take into account
parent proxy-report. Parents know their children better than
anyone else, and should be listened to when stating concerns about
their child’s fatigue. There is no ‘gold standard’ for fatigue
assessment in children and there are few studies, even in English,
that report on the validity of children’s self-report data on fatigue.
Thus, we collected patient self-reported and parent proxy-reported
data simultaneously, to provide additional data on fatigue,
particularly the data collected from younger children.
This study is the first to document the relationship between
corticosteroids and fatigue. Corticosteroid use was associated with
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Figure 3 Unadjusted mean scores of fatigue change pattern for patients with and without corticosteroid use over time: patient self-report.
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sfatigue in most domains reported by either patients or parents.
Most of the literature pertaining to adults have documented the
impact of chemotherapeutic agent use on fatigue, but there was no
literature to explain the relationship between corticosteroid use
and fatigue in children receiving chemotherapy.
Corticosteroid use was associated with higher fatigue scores and
reached the highest at day 5. The mechanism for the corticosteroid-
related fatigue found in this study is not clear. Increased
fatigue levels associated with the use of corticosteroids are in
conflict with the theory of hypothalamic-pituitary-adrenal axis in
which fatigue is assumed to be related to low circulating levels of
cortisol (Jones et al, 1998; Payne, 2004). Patients in this study
received long term and high doses of corticosteroids, which may
lead to complications of corticosteroid use, such as sleep
disruption, and therefore increasing the possibility of fatigue.
Further study is needed to examine other possible factors that may
cause fatigue, such as different cancer diagnoses, CTX agents, and
pre-existing sleep problems.
The patients included in this study received a variety of CTX
protocols, combining different chemotherapeutic agents, with or
without corticosteroids. Owing to the sample size of this study, we
did not analyse the relationship between fatigue levels and the use
of corticosteroids with specific chemotherapeutic agents. The
underlying mechanism of fatigue is not yet clear (Cleeland et al,
2003); this makes it difficult to develop scientific foundations for
intervention to relieve fatigue.
As the sample size used is small, generalising these results
without further study would be premature. However, this study
can be used by clinicians and researchers as a stimulus to conduct
more clinical assessments and conduct replications and expan-
sions of the present study. Clinicians can be more vigilant about
assessing fatigue and noting changes in the child’s fatigue level as
it relates to length of time since CTX and steroids were
administered. They could also note how fatigue relates to any
nausea, vomiting, or pain as well as changes in laboratory values.
Clinicians could also record the parent’s perception of their child’s
fatigue. Researchers could expand this study by recruiting more
children who had the same diagnosis and CTX protocols. To
conduct such studies it might require collecting data from different
places.
Our study supports the assumption that lower haemoglobin
level is a significant contributor to fatigue as previously described
in the literature (Shafqat et al, 2005). Routine clinical laboratory
check for haemoglobin in the current study setting varies, ranging
from 3 days to 1 month, depending on a patient’s treatment
protocol. The study findings do indicate that fatigue is likely to
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Figure 4 Unadjusted mean scores of fatigue change pattern for patients with and without corticosteroid use over time: parent proxy-report.
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svary over the course of time and treatment and that the timing of
haemoglobin measurements may not be frequent enough to catch
the rapidly changing fatigue level. Although the literature does not
report a conclusive relationship between haemoglobin and fatigue
(Hockenberry et al, 2003), this finding does suggest that frequent
haemoglobin check might increase the clinicians’ understanding of
fatigue that accompanies CTX.
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